Cytosorbents Crp

Company Profile

Cytosorbents Crp had its IPO on 2013-11-07 under the ticker symbol CTSO.

The company operates in the Healthcare sector and Medical Devices industry. Cytosorbents Crp has a staff strength of 198 employees.

Stock update

Shares of Cytosorbents Crp opened at $2.21 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.18 - $2.3, and closed at $2.19.

This is a -0.91% slip from the previous day's closing price.

A total volume of 152,025 shares were traded at the close of the day’s session.

In the last one week, shares of Cytosorbents Crp have slipped by -12.4%.

Cytosorbents Crp's Key Ratios

Cytosorbents Crp has a market cap of $136.70 million, indicating a price to book ratio of 1.3043 and a price to sales ratio of 1.4029.

In the last 12-months Cytosorbents Crp’s revenue was $35.45 million with a gross profit of $20.73 million and an EBITDA of $-30698652. The EBITDA ratio measures Cytosorbents Crp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Cytosorbents Crp’s operating margin was -89.21% while its return on assets stood at -28.09% with a return of equity of -73.88%.

In Q1, Cytosorbents Crp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 8.7%.

Cytosorbents Crp’s PE and PEG Ratio

Forward PE

106.383

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.74 per share while it has a forward price to earnings multiple of 106.383 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cytosorbents Crp’s profitability.

Cytosorbents Crp stock is trading at a EV to sales ratio of 1.3333 and a EV to EBITDA ratio of -1.2593. Its price to sales ratio in the trailing 12-months stood at 1.4029.

Cytosorbents Crp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$57.46 million

Total Liabilities

$10.44 million

Operating Cash Flow

$-682884.00

Capital Expenditure

$682884

Dividend Payout Ratio

0%

Cytosorbents Crp ended 2024 with $57.46 million in total assets and $0 in total liabilities. Its intangible assets were valued at $57.46 million while shareholder equity stood at $28.96 million.

Cytosorbents Crp ended 2024 with $0 in deferred long-term liabilities, $10.44 million in other current liabilities, 43851.00 in common stock, $-261323761.00 in retained earnings and $0 in goodwill. Its cash balance stood at $19.05 million and cash and short-term investments were $19.05 million. The company’s total short-term debt was $112,000 while long-term debt stood at $5.01 million.

Cytosorbents Crp’s total current assets stands at $28.17 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $5.53 million compared to accounts payable of $3.00 million and inventory worth $1.73 million.

In 2024, Cytosorbents Crp's operating cash flow was $-682884.00 while its capital expenditure stood at $682884.

Comparatively, Cytosorbents Crp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$2.19

52-Week High

$4.59

52-Week Low

$1.03

Analyst Target Price

$7

Cytosorbents Crp stock is currently trading at $2.19 per share. It touched a 52-week high of $4.59 and a 52-week low of $4.59. Analysts tracking the stock have a 12-month average target price of $7.

Its 50-day moving average was $3.11 and 200-day moving average was $2.86 The short ratio stood at 9.95 indicating a short percent outstanding of 0%.

Around 929.9% of the company’s stock are held by insiders while 3725.4% are held by institutions.